Product
dexmedetomidine
8 clinical trials
11 indications
Indication
MRI SedationIndication
Ischemia/Reperfusion InjuryIndication
PheochromocytomaIndication
Post-operative Nausea and VomitingIndication
Sleeve GastrectomyIndication
InsomniaIndication
PainIndication
PostoperativeIndication
Laryngeal CancerIndication
Delirium on EmergenceIndication
Kidney FailureClinical trial
A PHASE 3/4 RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING STUDY OF THE SAFETY AND EFFICACY OF DEXMEDETOMIDINE (DEX) USED WITH PROPOFOL (PRO) AS NEEDED FOR PROCEDURAL SEDATION OF PEDIATRIC SUBJECTS ≥1 MONTH TO <17 YEARS OF AGE UNDERGOING MRI SCANSStatus: Completed, Estimated PCD: 2021-11-02
Clinical trial
Effect of Dexmedetomidine Preconditioning on Myocardial Ischemia-reperfusion : a Randomized, Double-blind Clinical TrialStatus: Completed, Estimated PCD: 2023-05-30
Clinical trial
The Effects of Perioperative Dexmedetomidine Infusion on Hemodynamic Stability During Laparoscopic Adrenalectomy for Pheochromocytoma: a Randomized StudyStatus: Completed, Estimated PCD: 2021-03-26
Clinical trial
Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve GastrectomyStatus: Completed, Estimated PCD: 2019-03-30
Clinical trial
The Effect of Dexmedetomidine on Patients With Chronic Insomnia and Its Influence on Circadian Rhythm:Randomized Clinical Trial, Double BlindStatus: Completed, Estimated PCD: 2023-06-30
Clinical trial
Efficacy of Adding Dexmedetomidine as Adjuvant With Bupivacaine in Ultrasound-guided Intermediate Cervical Plexus Block for Thyroidectomy Surgery: Randomized Controlled StudyStatus: Completed, Estimated PCD: 2023-10-01
Clinical trial
Ketofol vs Dexmedetomidine for Preventing Post-operative Delirium in Elderly Patients Undergoing Intestinal Obstruction Surgeries. A Randomized Controlled StudyStatus: Completed, Estimated PCD: 2022-11-01
Clinical trial
Evaluation of Renal Protection Of Dexmedetomidine Versus Midazolam As a Sedative For Septic Patients In Intensive Care UnitStatus: Recruiting, Estimated PCD: 2023-11-12